The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Advancing multidisciplinary management of oligometastatic gastroesophageal cancer
Radka Obermannova, MD, PhD, Masaryk University, Brno, Czech Republic, highlights the significance of multidisciplinary care in a session at the European Society for Medical Oncology (ESMO) 2024 Congress, which brought together surgeons, radiation oncologists, medical oncologists, among others, to discuss the complexities of oligometastatic disease. While there is a European consensus on its definition, not all countries have accepted it. The session emphasized the need for more biomarker-oriented studies and next-generation trials to improve the understanding of the biology of oligometastatic disease and optimize treatment strategies. This interview took place at the ESMO 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
